Home
Case studies
Expert interviews
eLearning
News

Treatment options for
metastatic urothelial carcinoma:

News

Provided by our news bureau, medwireNews, our conference coverage is a useful resource for healthcare practitioners to keep up to date with the latest medical news. Stay informed on the recent advances and clinical developments presented at key congresses, by watching leading experts analyze the key results and discussing the latest research studies in our videos below.

Our conference coverage from the ASCO 22 Annual Meeting, ESMO and ASCO GU is now available to view here.

Article: High BMI tied to improved ICI outcomes in metastatic UC patients

Access Here
Conference coverage from ESMO 2022

Article: Real-world study corroborates maintenance avelumab advanced UC benefit

Access Here
Conference coverage from ESMO 2022

Article: 'Very strong' response to first-line enfortumab vedotin–pembrolizumab in advanced urothelial cancer

Access Here
Conference coverage from ESMO 2022

Video: Exploratory data suggest potential of epigenetic biomarkers in advanced UC

Watch Now
Conference coverage from ESMO 2022

Video: IMvigor130 analysis highlights need to standardize PD-L1 expression assessment

Watch Now
Conference coverage from ESMO 2022

Video: Latest EV-103 update further supports enfortumab vedotin for untreated advanced UC

Watch Now
Conference coverage from ESMO 2022

Article: JAVELIN Bladder 100 analysis hints at epigenetic marker of avelumab benefit

Access Here
Conference coverage from ESMO 2022

Article: JAVELIN Bladder 100 exploratory analyses point to wide use of maintenance avelumab

Access Here
Conference Coverage from ASCO 22 Annual Meeting

Video: EV-301 update reinforces third-line enfortumab vedotin benefit in advanced UC

Watch Now
Conference Coverage from ASCO 22 Annual Meeting

Video: ATLANTIS rules out cabozantinib as a maintenance option for mUC

Watch Now
Conference Coverage from ASCO 22 Annual Meeting

Video: COSMIC-021 cohorts continue to show encouraging cabozantinib–atezolizumab advanced UC activity

Watch Now
Conference Coverage from ASCO 22 Annual Meeting

Article: No benefit of maintenance cabozantinib in unselected patients with mUC

Access Here
Conference Coverage from ASCO 22 Annual Meeting

Article: Enfortumab vedotin offers sustained benefit over 2 years in advanced UC

Access Here
Conference Coverage from ASCO 22 Annual Meeting

Article: More support from COSMIC-021 for cabozantinib–atezolizumab potential in advanced UC

Access Here
Conference Coverage from ASCO 22 Annual Meeting

Video: First-line avelumab investigated in cisplatin-unfit advanced UC patients

Watch Now
Conference Coverage from ASCO GU

Article: Maintenance rucaparib feasible for platinum-responsive mUC with DRD biomarkers

Access Here
Conference Coverage from ASCO GU

Video: Potential of sacituzumab govitecan plus pembrolizumab demonstrated in mUC patients

Watch Now
Conference Coverage from ASCO GU

Article: Sacituzumab govitecan–pembrolizumab combo encouraging for pretreated mUC

Access Here
Conference Coverage from ASCO GU

Article: BAYOU hints at potential of durvalumab–olaparib in mutated metastatic UC

Access Here
Conference Coverage from ASCO GU

Article: Maintenance niraparib fails to improve advanced urothelial cancer PFS

Access Here
Conference Coverage from ASCO GU

Video: ATLANTIS points to maintenance benefit of rucaparib in mUC

Watch Now
Conference Coverage from ASCO GU

News and expert video interviews from the ESMO Congress

Access Here
Conference Coverage from ESMO Congress
© 2022 Springer Healthcare Ltd. Part of the Springer Nature Group.
Privacy policy
Terms & conditions
Manage cookies/Do not sell my data
Contact us